| 1 | 1 | | |
|---|
| 2 | 2 | | HOUSE BILL 428 |
|---|
| 3 | 3 | | By Stinnett |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | SENATE BILL 610 |
|---|
| 6 | 6 | | By Massey |
|---|
| 7 | 7 | | |
|---|
| 8 | 8 | | |
|---|
| 9 | 9 | | SB0610 |
|---|
| 10 | 10 | | 001606 |
|---|
| 11 | 11 | | - 1 - |
|---|
| 12 | 12 | | |
|---|
| 13 | 13 | | AN ACT to amend Tennessee Code Annotated, Title 56 |
|---|
| 14 | 14 | | and Title 71, relative to continuous glucose |
|---|
| 15 | 15 | | monitoring. |
|---|
| 16 | 16 | | |
|---|
| 17 | 17 | | BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE: |
|---|
| 18 | 18 | | SECTION 1. Tennessee Code Annotated, Title 71, Chapter 5, Part 1, is amended by |
|---|
| 19 | 19 | | adding the following as a new section: |
|---|
| 20 | 20 | | (a) As used in this section: |
|---|
| 21 | 21 | | (1) "Bureau" means the bureau of TennCare; |
|---|
| 22 | 22 | | (2) "Continuous glucose monitor" or "CGM" means a device that |
|---|
| 23 | 23 | | automatically and continuously monitors a user's blood glucose levels through |
|---|
| 24 | 24 | | the use of a sensor on the user's body, and enables the user to read the blood |
|---|
| 25 | 25 | | glucose level; and |
|---|
| 26 | 26 | | (3) "Enrollee" means an individual enrolled in TennCare. |
|---|
| 27 | 27 | | (b) The bureau shall provide coverage on behalf of an enrollee for a CGM if: |
|---|
| 28 | 28 | | (1) The patient: |
|---|
| 29 | 29 | | (A) Has a diagnosis of Type 1 diabetes mellitus; |
|---|
| 30 | 30 | | (B) Has a diagnosis of gestational diabetes; |
|---|
| 31 | 31 | | (C) Has a history of problematic hypoglycemia; or |
|---|
| 32 | 32 | | (D) Requires the use of insulin; or |
|---|
| 33 | 33 | | (2) The patient has a diagnosis of Type 2 diabetes mellitus and the |
|---|
| 34 | 34 | | patient meets at least one (1) of the following criteria: |
|---|
| 35 | 35 | | |
|---|
| 36 | 36 | | |
|---|
| 37 | 37 | | - 2 - 001606 |
|---|
| 38 | 38 | | |
|---|
| 39 | 39 | | (A) Documented hemoglobin A1C greater than or equal to seven |
|---|
| 40 | 40 | | percent (7%) measured within six (6) months of a request for laboratory |
|---|
| 41 | 41 | | blood work; |
|---|
| 42 | 42 | | (B) Documented frequent hypoglycemia or nocturnal |
|---|
| 43 | 43 | | hypoglycemia episodes with blood glucose levels of less than fifty |
|---|
| 44 | 44 | | milligrams per deciliter (50 mg/dl); |
|---|
| 45 | 45 | | (C) Documented history of hypoglycemic unawareness; |
|---|
| 46 | 46 | | (D) Dawn phenomenon with fasting blood sugars frequently |
|---|
| 47 | 47 | | exceeding two hundred milligrams per deciliter (200 mg/dl); or |
|---|
| 48 | 48 | | (E) History of emergency room visits or hospitalizations related to |
|---|
| 49 | 49 | | ketoacidosis or hypoglycemia. |
|---|
| 50 | 50 | | (c) The mandatory coverage under subsection (b) is required only if the CGM is |
|---|
| 51 | 51 | | prescribed by or in consultation with an endocrinologist or healthcare practitioner with |
|---|
| 52 | 52 | | experience in diabetes management who documents that the enrollee meets the criteria |
|---|
| 53 | 53 | | under subdivision (b)(1) or subdivision (b)(2). |
|---|
| 54 | 54 | | SECTION 2. This act takes effect January 1, 2026, the public welfare requiring it. |
|---|